# US 11,078,261 B2 · Anti-N3pGlu amyloid beta peptide antibodies and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,078,261 B2
- Document ID: US11078261B2
- Status: Granted
- Kind: B2
- Application number: 16/843,503
- Filed: 2020-04-08
- Published: 2020-08-20
- Granted: 2021-08-03
- Earliest claimed: 2017-04-20
- Assignees: Eli Lilly and Company
- Applicants: Eli Lilly and Company
- Inventors: Ronald Bradley Demattos; Jirong Lu; Ying Tang
- Web page: https://patentgrep.com/patent/US11078261B2

## CPC

- C07K 16/18: against material from animals or humans
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K 2039/505: {comprising antibodies}
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/90: characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Antibodies to human N3pGlu Aβ, compositions comprising such N3pGlu Aβ antibodies, and methods of using such N3pGlu Aβ antibodies for the treatment of a disease characterized by deposition of Aβ including clinical or pre-clinical Alzheimer's disease, Down's syndrome, and clinical or pre-clinical cerebral amyloid angiopathy.

## Claims

### Claim 1

A DNA molecule comprising a polynucleotide that encodes an antibody heavy chain comprising SEQ ID NO:12.

### Claim 2 (depends on 1)

The DNA molecule of claim 1, wherein the polynucleotide comprises SEQ ID NO: 15.

### Claim 3

A DNA molecule comprising a polynucleotide that encodes an antibody light chain comprising SEQ ID NO:13.

### Claim 4 (depends on 3)

The DNA molecule of claim 3, wherein the polynucleotide comprises SEQ ID NO: 16.

### Claim 5

A DNA molecule comprising a polynucleotide sequence that encodes an antibody heavy chain comprising SEQ ID NO: 12 and a polynucleotide sequence that encodes an antibody light chain comprising SEQ ID NO: 13.

### Claim 6 (depends on 5)

The DNA molecule of claim 5, wherein the polynucleotide sequence that encodes the antibody heavy chain is SEQ ID NO:15, and the polynucleotide sequence that encodes the antibody light chain is SEQ ID NO:16.

### Claim 7

A mammalian cell transformed with a DNA molecule comprising: a polynucleotide that encodes an antibody heavy chain comprising SEQ ID NO: 12 and/or a polynucleotide that encodes an antibody light chain comprising SEQ ID NO: 13.

### Claim 8 (depends on 7)

The mammalian cell of claim 7 transformed with the DNA molecule comprising: a polynucleotide that encodes the antibody heavy chain comprising SEQ ID NO: 12 and a polynucleotide that encodes the antibody light chain comprising SEQ ID NO: 13.

### Claim 9

A process for producing an antibody comprising two heavy chains and two light chains, wherein each heavy chain comprises SEQ ID NO: 12, and each light chain comprises SEQ ID NO: 13, and wherein the process comprises: a) expressing the antibody under suitable conditions in a mammalian cell, and b) recovering the expressed antibody.